期刊文献+

化肝汤1号对酒精性肝纤维化肝功能的调节作用研究 被引量:1

The Regulation of Liver Function Liver Soup 1 on Alcohol-induced Liver Fibrosis
下载PDF
导出
摘要 目的观察活血化瘀、软坚散结药配伍治疗肝纤维化时对肝功能的影响。方法采用自制方剂化肝汤1号(醋鳖甲、黄芩、柴胡、赤芍等)治疗肝纤维化60例。结果丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酸转移酶(GGT)、AST/ALT治疗组治疗前为(61.77±10.36)U/L、(134.53±23.09)U/L、(123.23±17.31)U/L、(2.18±0.13),治疗后为(33.33±6.50)U/L、(56.27±10.92)U/L、(60.20±7.40)U/L、(1.71±0.27)。对照组治疗前为(59.03±7.90)U/L、(123.30±14.21)U/L、(120.60±13.84)U/L、(2.09±0.07),治疗后为(42.70±6.52)U/L、(84.67±11.82)U/L、(81.63±10.17)U/L、(1.99±0.16),治疗组和对照组治疗前后比较差异均有统计学意义(P<0.05),治疗组与对照组治疗后比较差异均有统计学意义(P<0.05)。结论化肝汤1号可有效的降低肝细胞的损害程度,促进受损细胞修复,从而改善肝功能。 Objective To observe the blood circulation,endometriosis drug compatibility of the treatment of liver fibrosis on liver function.Methods Using self-prescription of liver soup 1(vinegar turtle,skullcap,bupleurum root,red peony,etc.) in the treatment of liver fibrosis in 60 cases.Results ALT,AST,GGT,AST / ALT before treatment to(61.77±10.36)U/L、(134.53±23.09)U/L、(123.23±17.31)U/L、(2.18±0.13),after treatment(33.33±6.50)U/L、(56.27±10.92)U/L、(60.20±7.40)U/L、(1.71±0.27).Control group before treatment(59.03±7.90)U/L、(123.30±14.21)U/L、(120.60±13.84)U/L、(2.09±0.07),after treatment(42.70±6.52)U/L、(84.67±11.82)U/L、(81.63±10.17)U/L、(1.99±0.16),treatment and control groups before and after treatment were significantly differences(P0.05),treatment group and control group after treatment(P0.05),there are significant differences.Conclusion The liver soup 1 can effectively reduce the degree of liver cell damage and promote repair of damaged cells,thus improving liver function.
出处 《临床合理用药杂志》 2011年第07X期21-22,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 肝纤维化 肝功能 化肝汤1号 Liver fibrosis Liver function Liver soup 1
  • 相关文献

参考文献3

二级参考文献19

  • 1胡国平,刘凯,赵连三.多烯磷脂酰胆碱(易善复)治疗酒精性肝病和脂肪肝的系统评价[J].肝脏,2005,10(1):5-7. 被引量:108
  • 2Lok AS,McMahon BJ; Practice Guidelines Committee,American Association for the Study of Liver Diseases (AASLD).Chronic hepatitis B:update of recommendations.Hepatology,2004,39:857-861.
  • 3Farrell GC,George J,Pauline de la M.Hall and McCullough A J,eds.Fatty liver disease:NASH and related disorders.Oxford:Blackwell Publishing,2005,1-22.
  • 4American Gastroenterological Association.American Gastroenterological Association Medical Position Statement:nonalcoholic fatty liver disease.Gastroenterology,2002,123:1702-1704.
  • 5Sanyal AJ.AGA technical review on nonalcoholic fatty liver disease.Gastroenterology,2002,123:1705-1725.
  • 6Ramesh S,Sanyal AJ.Evaluation and management of non-alcoholic steatohepatitis.J Hepatol,2005,42:S2-S12.
  • 7Eckel RH,Grundy SM,Zimmet PZ.The metabolic syndrome.Lancet,2005,365:1415-1428.
  • 8Graif M,Yanuka M,Baraz M,et al.Quantitative estimation of attenuation in ultrasound video images:correlation with histology in diffuse liver disease.Invest Radiol,2000,35:319-324.
  • 9Ataseven H,Yildrim MH,Yalniz M,et al.Correlation between computerized tomographic findings and histopathologic grade/stage in non-alcoholic steatohepatitis.J Hepatol,2003,38(Suppl 2):A4177.
  • 10Schwimmer JB,Behling C,Newbury R,et al.Histopathology of pediatric nonalcoholic fatty liver disease.Hepatology,2005,42:641-9.

共引文献701

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部